- Roche (RHHBY -0.4%) and ImmunoGen's (IMGN +1.8%) Kadcyla gets European marketing approval, triggering a $5M milestone payment to IMGN.
- The drug is approved for adults with "HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination." (PR)
- The news was expected after the CHMP gave the drug a positive opinion back in September.
Kadcyla wins EU marketing approval triggering milestone payment for ImmunoGen
Nov 20 2013, 11:33 ET